1 of 1
HOUSE DOCKET, NO. 2903 FILED ON: 1/16/2025
HOUSE . . . . . . . . . . . . . . . No. 1359
The Commonwealth of Massachusetts
_________________
PRESENTED BY:
Marjorie C. Decker
_________________
To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:
The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:
An Act relative to capping the price of epinephrine.
_______________
PETITION OF:
NAME:DISTRICT/ADDRESS :DATE ADDED:Marjorie C. Decker25th Middlesex1/16/2025 1 of 6
HOUSE DOCKET, NO. 2903 FILED ON: 1/16/2025
HOUSE . . . . . . . . . . . . . . . No. 1359
By Representative Decker of Cambridge, a petition (accompanied by bill, House, No. 1359) of
Marjorie C. Decker relative to the price of epinephrine. Health Care Financing.
The Commonwealth of Massachusetts
_______________
In the One Hundred and Ninety-Fourth General Court
(2025-2026)
_______________
An Act relative to capping the price of epinephrine.
Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority
of the same, as follows:
1 SECTION 1. Subsection (b) of section 26 of chapter 342 of the Acts of 2024, is hereby
2amended by inserting after the word “members”, the following words:- ; and the following acute
3condition (i) anaphylaxis.
4 SECTION 2. Subsection (c) of said section 26 of said chapter 342, as so appearing, is
5hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine
6delivered via an autoinjector as the drug used to treat anaphylaxis.
7 SECTION 3. Said subsection (c) of said section 26 of said chapter 342, as so appearing,
8is hereby further amended by inserting after the word “condition”, the following words:- or acute
9condition.
10 SECTION 4. Said clause (v) of said subsection (c) of said section 26 of said chapter 342,
11as so appearing, is hereby further amended by inserting after the word “condition”, the following
12words:- or acute condition. 2 of 6
13 SECTION 5. Subsection (d) of said section 26 of said chapter 342, as so appearing, is
14hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine
15delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall
16not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a
17two-pack of epinephrine autoinjectors.
18 SECTION 6. Subsection (b) of section 28 of chapter 342 of the Acts of 2024, is hereby
19amended by inserting after the word “enrollees”, the following words:- ; and the following acute
20condition (i) anaphylaxis.
21 SECTION 7. Subsection (c) of said section 28 of said chapter 342, as so appearing, is
22hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine
23delivered via an autoinjector as the drug used to treat anaphylaxis.
24 SECTION 8. Said subsection (c) of said section 28 of said chapter 342, as so appearing,
25is hereby further amended by inserting after the word “condition”, the following words:- or acute
26condition.
27 SECTION 9. Said clause (v) of said subsection (c) of said section 28 of said chapter 342,
28as so appearing, is hereby further amended by inserting after the word “condition”, the following
29words:- or acute condition.
30 SECTION 10. Subsection (d) of said section 28 of said chapter 342, as so appearing, is
31hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine
32delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall
33not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a
34two-pack of epinephrine autoinjectors. 3 of 6
35 SECTION 11. Subsection (b) of section 31 of chapter 342 of the Acts of 2024, is hereby
36amended by inserting after the word “enrollees”, the following words:- ; and the following acute
37condition (i) anaphylaxis.
38 SECTION 12. Subsection (c) of said section 31 of said chapter 342, as so appearing, is
39hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine
40delivered via an autoinjector as the drug used to treat anaphylaxis.
41 SECTION 13. Said subsection (c) of said section 31 of said chapter 342, as so appearing,
42is hereby further amended by inserting after the word “condition”, the following words:- or acute
43condition.
44 SECTION 14. Said clause (v) of said subsection (c) of said section 31 of said chapter
45342, as so appearing, is hereby further amended by inserting after the word “condition”, the
46following words:- or acute condition.
47 SECTION 15. Subsection (d) of said section 31 of said chapter 342, as so appearing, is
48hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine
49delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall
50not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a
51two-pack of epinephrine autoinjectors.
52 SECTION 16. Subsection (b) of section 33 of chapter 342 of the Acts of 2024, is hereby
53amended by inserting after the word “enrollees”, the following words:- ; and the following acute
54condition (i) anaphylaxis. 4 of 6
55 SECTION 17. Subsection (c) of said section 33 of said chapter 342, as so appearing, is
56hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine
57delivered via an autoinjector as the drug used to treat anaphylaxis.
58 SECTION 18. Said subsection (c) of said section 33 of said chapter 342, as so appearing,
59is hereby further amended by inserting after the word “condition”, the following words:- or acute
60condition.
61 SECTION 19. Said clause (v) of said subsection (c) of said section 33 of said chapter
62342, as so appearing, is hereby further amended by inserting after the word “condition”, the
63following words:- or acute condition.
64 SECTION 20. Subsection (d) of said section 33 of said chapter 342, as so appearing, is
65hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine
66delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall
67not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a
68two-pack of epinephrine autoinjectors.
69 SECTION 21. Subsection (b) of section 34 of chapter 342 of the Acts of 2024, is hereby
70amended by inserting after the word “enrollees”, the following words:- ; and the following acute
71condition (i) anaphylaxis.
72 SECTION 22. Subsection (c) of said section 34 of said chapter 342, as so appearing, is
73hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine
74delivered via an autoinjector as the drug used to treat anaphylaxis. 5 of 6
75 SECTION 23. Said subsection (c) of said section 34 of said chapter 342, as so appearing,
76is hereby further amended by inserting after the word “condition”, the following words:- or acute
77condition.
78 SECTION 24. Said clause (v) of said subsection (c) of said section 34 of said chapter
79342, as so appearing, is hereby further amended by inserting after the word “condition”, the
80following words:- or acute condition.
81 SECTION 25. Subsection (d) of said section 34 of said chapter 342, as so appearing, is
82hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine
83delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall
84not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a
85two-pack of epinephrine autoinjectors.
86 SECTION 26. Subsection (b) of section 35 of chapter 342 of the Acts of 2024, is hereby
87amended by inserting after the word “enrollees”, the following words:- ; and the following acute
88condition (i) anaphylaxis.
89 SECTION 27. Subsection (c) of said section 35 of said chapter 342, as so appearing, is
90hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine
91delivered via an autoinjector as the drug used to treat anaphylaxis.
92 SECTION 28. Said subsection (c) of said section 35 of said chapter 342, as so appearing,
93is hereby further amended by inserting after the word “condition”, the following words:- or acute
94condition. 6 of 6
95 SECTION 29. Said clause (v) of said subsection (c) of said section 35 of said chapter
96342, as so appearing, is hereby further amended by inserting after the word “condition”, the
97following words:- or acute condition.
98 SECTION 30. Subsection (d) of said section 35 of said chapter 342, as so appearing, is
99hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine
100delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall
101not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a
102two-pack of epinephrine autoinjectors.
103 SECTION 31. This act shall apply to all contracts entered into, renewed or amended on
104or after July 1, 2026.